{
    "clinical_study": {
        "@rank": "48753", 
        "arm_group": [
            {
                "arm_group_label": "selumetinib; itraconazole; selumetinib + itraconazole", 
                "arm_group_type": "Experimental", 
                "description": "Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule"
            }, 
            {
                "arm_group_label": "selumetinib; fluconazole; selumetinib + fluconazole", 
                "arm_group_type": "Experimental", 
                "description": "Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg."
            }
        ], 
        "brief_summary": {
            "textblock": "Study to assess the effect of Itraconazole and Fluconazole on the pharmacokinetics of\n      Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Male Volunteers"
        }, 
        "brief_title": "To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumours", 
        "detailed_description": {
            "textblock": "A Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole\n      and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of\n      Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: 1. Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive)\n        and weigh at least 50 kg and no more than 100 kg. 2. Female subjects of non-childbearing\n        potential. 3. Have a calculated creatinine clearance (CrCL) >50 mL/min using the\n        Cockcroft-Gault formula.\n\n        Exclusion Criteria: 1. Subjects of Japanese or non-Japanese Asian ethnicity. 2. Any one\n        parent or grandparent (maternal or paternal) is Japanese or non-Japanese. Asian (ie,\n        China, Taiwan, Korea, Philippines, Thailand, Vietnam and Malaysia). Asian Indians are\n        acceptable. 3. Current or past history of central serous retinopathy or retinal vein\n        thrombosis,intra-ocular pressure >21 mmHg or uncontrolled glaucoma. 4. Any clinically\n        relevant abnormal findings in physical examination, hematology, clinical chemistry,\n        urinalysis, vital signs or ECG at baseline in the opinion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093728", 
            "org_study_id": "D1532C00083"
        }, 
        "intervention": [
            {
                "arm_group_label": "selumetinib; itraconazole; selumetinib + itraconazole", 
                "description": "Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A", 
                "intervention_name": "selumetinib", 
                "intervention_type": "Drug", 
                "other_name": "(AZD6244; ARRY-142866) ( Hyd-Sulfate)"
            }, 
            {
                "arm_group_label": "selumetinib; itraconazole; selumetinib + itraconazole", 
                "description": "Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:", 
                "intervention_name": "itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "selumetinib; itraconazole; selumetinib + itraconazole", 
                "description": "Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.", 
                "intervention_name": "itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "selumetinib; itraconazole; selumetinib + itraconazole", 
                "description": "Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.", 
                "intervention_name": "selumetinib", 
                "intervention_type": "Drug", 
                "other_name": "(AZD6244; ARRY-142866) ( Hyd-Sulfate)"
            }, 
            {
                "arm_group_label": "selumetinib; fluconazole; selumetinib + fluconazole", 
                "description": "Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.", 
                "intervention_name": "selumetinib", 
                "intervention_type": "Drug", 
                "other_name": "(AZD6244; ARRY-142866) ( Hyd-Sulfate)"
            }, 
            {
                "arm_group_label": "selumetinib; fluconazole; selumetinib + fluconazole", 
                "description": "Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2  treatment D.", 
                "intervention_name": "fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "selumetinib; fluconazole; selumetinib + fluconazole", 
                "description": "Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E", 
                "intervention_name": "fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "selumetinib; fluconazole; selumetinib + fluconazole", 
                "description": "Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E", 
                "intervention_name": "selumetinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Phase I, healthy, pharmacokinetics", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years", 
        "other_outcome": {
            "description": "Assessments performed during each of the 6 treatments", 
            "measure": "Safety variables (adverse events, physical examinations, opthalmologic assessements, vital signs, clinical laboratory assessments and 12 lead electrocardiograms)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (Day-1) up to Day 24"
        }, 
        "overall_official": {
            "affiliation": "Quintiles 6700 W 115th Street, Kansas, US", 
            "last_name": "David R Mathews, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Samples taken during each of the 6 treatments", 
            "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC)", 
            "safety_issue": "No", 
            "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093728"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of area under the plasma concentration-time from time zero to the time of the last quantifiable concentration (AUC(0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of area under the plasma concentration-time curve from time zero to 12 hours post-dose AUC(0-12)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of time to Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assesement of apparent oral plasma clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assesement of apparent volume at distribution steady state, (MRT)*CL/F (Vss/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assesement of apparent volume at distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of terminal rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of AUC metabolite to parent ratio (MRAUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of Cmax metabolite to parent ratio (MRCmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }, 
            {
                "description": "Samples taken during each of the 6 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assesement of mean residence time (MRT)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}